Compile Data Set for Download or QSAR
maximum 50k data
Found 212 Enz. Inhib. hit(s) with all data for entry = 8886
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426423(1-(2-((2R,5R)-5-((3- (difluoromethyl)imidazo[1,2-a...)
Affinity DataIC50:  5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426469((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((3-br...)
Affinity DataIC50:  7.30nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426387((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((3-br...)
Affinity DataIC50:  8.90nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426407((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((3-ch...)
Affinity DataIC50:  9.10nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426409(1-(2-((2R,5R)-5-((3- chloroimidazo[1,2-alpha] pyr...)
Affinity DataIC50:  9.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426425((2-(2H-tetrazol-2-yl)phenyl)((2R,5R)-5- ((3-(difl...)
Affinity DataIC50:  9.60nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426451((2-(2H-1,2,3-triazol-2-yl)thiophen-3-yl)((2R,5R)-2...)
Affinity DataIC50:  9.80nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426386((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-(imida...)
Affinity DataIC50:  10.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426421((2-(2H-1,2,3-triazol-2-yl)thiophen-3- yl)((2R,5R)-...)
Affinity DataIC50:  10.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426407((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((3-ch...)
Affinity DataIC50:  12.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426413((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((3-fl...)
Affinity DataIC50:  12.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426440(1-(2-((2R,5R)-2-methyl-5-((3- (trifluoromethyl)imi...)
Affinity DataIC50:  12.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((3-br...)
Affinity DataIC50:  13.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426390(1-(2-((2R,5R)-2-methyl-5-((2- methylimidazo[1,2-al...)
Affinity DataIC50:  13.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426411((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((3-ch...)
Affinity DataIC50:  13.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426454((4-fluoro-2-(2H-1,2,3-triazol-2- yl)phenyl)((2R,5R...)
Affinity DataIC50:  14nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426487((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-(imida...)
Affinity DataIC50:  14nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426453(1-(2-((2R,5R)-2-methyl-5- (pyrazolo[1,5-alpha]pyr...)
Affinity DataIC50:  14.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426410((2-(2H-1,2,3-triazol-2- yl)thiophen-3-yl)((2R,5R)-...)
Affinity DataIC50:  14.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426447(((2R,5R)-2-methyl-5-((3-(trifluoromethyl)imidazo[1...)
Affinity DataIC50:  14.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426466(((2R,5R)-2-methyl-5-(pyrazolo[1,5-a]pyrazin-4-ylox...)
Affinity DataIC50:  15.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426468((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  15.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426424(((2R,5R)-5-((3- (difluoromethyl)imidazo[1,2-alpha]...)
Affinity DataIC50:  15.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426433((2-(1H-pyrazol-1-yl)pyridin-3- yl)((2R,5R)-5-((3- ...)
Affinity DataIC50:  15.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426452((4-(2H-1,2,3-triazol-2-yl)thiophen-3- yl)((2R,5R)-...)
Affinity DataIC50:  16nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426415((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  16.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426474((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  16.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426445((2-(2,2- difluoroethoxy)pyridin- 3-yl)((2R,5R)-2-m...)
Affinity DataIC50:  17.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426419((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((3-(d...)
Affinity DataIC50:  17.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426478((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  17.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426441((2-(2H-tetrazol-2- yl)phenyl)((2R,5R)-2- methyl-5-...)
Affinity DataIC50:  19nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426472((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  19.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426439((2-(2H-1,2,3-triazol-2-yl)thiophen-3-yl)((2R,5R)-2...)
Affinity DataIC50:  20.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426467((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  20.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426456(((2R,5R)-2-methyl-5-(pyrazolo[1,5- alpha]pyrazin-4...)
Affinity DataIC50:  20.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426417((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  21nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426434(((2R,5R)-5-((3- (difluoromethyl)imidazo[1,2-alpha]...)
Affinity DataIC50:  21.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426387((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  22.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426488((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  23.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426412(((2R,5R)-5-((3-chloroimidazo[1,2-a]pyrazin-8-yl)am...)
Affinity DataIC50:  23.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426446((2-(1H-pyrazol-1- yl)pyridin-3-yl) ((2R,5R)-2-meth...)
Affinity DataIC50:  24nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426435(((2R,5R)-5-((3-(difluoromethyl)imidazo[1,2-a]pyraz...)
Affinity DataIC50:  24.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426477((2-ethoxyphenyl)((2R,5R)- 2-methyl-5- (oxazolo[5,4...)
Affinity DataIC50:  24.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426429(US10526336, Example 48 | methyl 2-((2R,5R)-5-((3- ...)
Affinity DataIC50:  24.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426431(((2R,5R)-5-((3- (difluoromethyl)imidazo[1,2-alpha]...)
Affinity DataIC50:  26.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426450((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  26.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426388((2-(2H-1,2,3-triazol-2-yl)thiophen-3-yl)((2R,5R)-2...)
Affinity DataIC50:  27.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426489((2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-2-methyl...)
Affinity DataIC50:  27.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426457((2-(2H-tetrazol-2-yl)phenyl)((2R,5R)- 2-methyl-5-...)
Affinity DataIC50:  27.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 212 total ) | Next | Last >>
Jump to: